Abstract
Blood cancer (leukaemia ) and lymph node cancer (lymphoma ) are increasingly being recognized as clinically heterogeneous diseases. It is therefore important to find markers with predictive value for disease course and survival. Such prognostic markers may also be used for treatment choices in individual patients. In addition, it is becoming increasingly important to sensitively and accurately monitor the effect of the chosen therapy and to adapt the therapy if necessary. This chapter highlights the role of molecular diagnostics in making a diagnosis, for prognostic classification, and for monitoring of lymphoid malignancies (leukaemias and lymphoma s). In these assays, especially immunoglobulin (IG) and T-cell receptor (TCR) gene rearrangements are being used as molecular markers. Following an introduction on IG/TCR molecules and the basic mechanisms of the rearrangement processes in the IG/TCR gene complexes, strategies are discussed in which these DNA markers are used for molecular diagnostics of lymphoid malignancies. Next, a brief overview of other molecular markers and their applications in leukaemia and lymphoma diagnostics is given. Finally, new developments are discussed that in time will impact on molecular diagnostics of lymphoid malignancies.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Baliakas P, Hadzidimitriou A, Sutton LA, Minga E, Agathangelidis A, Tsanousa A, Scarfo L, Davis Z, Yan XJ, Shanafelt T, Plevova K, Sandberg Y, Vojdeman FJ, Boudjogra M, Tzenou T, Chatzouli M, Chu CC, Veronese S, Gardiner A, Mansouri L, Smedby KE, Bredo Pedersen L, Moreno D, van Lom K, Giudicelli V, Shkurova Francova H, Nguyen-Khac F, Panagiotidis P, Juliusson G, Angelis L, Anagnostopoulos A, Lefranc MP, Trentin L, Catherwood M, Montillo M, Geisler G, Langerak AW, Pospisilova S, Chiorazzi N, Oscier D, Jelinek D, Darzentas N, Belessi C, Davi F, Rosenquist R, Ghia P, Stamatopoulos K. Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study. Lancet Hematol. 2014;1:e74–84.
Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, Buchbinder A, Budman D, Dittmar K, Kolitz J, Lichtman SM, Schulman P, Vinciguerra VP, Rai KR, Ferrarini M. Chiorazzi N Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840–7.
Flohr T, Schrauder A, Cazzaniga G, Panzer-Grümayer R, van der Velden V, Fischer S, Stanulla M, Basso G, Niggli FK, Schäfer BW, Sutton R, Koehler R, Zimmermann M, Valsecchi MG, Gadner H, Masera G, Schrappe M, van Dongen JJ, Biondi A, Bartram CR. International BFM Study Group (I-BFM-SG). Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia. 2008;22:771–82.
Ghia P, Stamatopoulos K, Belessi C, Moreno C, Stilgenbauer S, Stevenson F, Davi F, Rosenquist R. ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia. Leukemia. 2007;21:1–3.
Goulden N, Bader P, van der Velden V, Moppett J, Schilham M, Masden HO, Krejci O, Kreyenberg H, Lankester A, Révész T, Klingebiel T, van Dongen J. Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia. Br J Haematol. 2003;122:24–9.
Hamblin TJ, Davis Z, Gardiner A, Oscier DG. Stevenson FK Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848–54.
Langerak AW, Groenen PJTA, van Krieken JHJM, van Dongen JJM. Ig/TCR clonality diagnostics. Exp Opin Med Diagn. 2007;1:451–61.
Langerak AW, Davi F, Ghia P, Hadzidimitriou A, Murray F, Potter KN, Rosenquist R, Stamatopoulos K, Belessi C. Immunoglobulin sequence analysis and prognostication in CLL: guidelines from the ERIC Review Board for reliable interpretation of problematic cases. Leukemia. 2011;25:979–84.
Langerak AW, Groenen PJTA, Brüggemann M, Beldjord K, Bellan C, Bonello L, Boone E, Carter I, Catherwood M, Davi F, Delfau-Larue MH, Diss T, Evans PAS, Gameiro P, Garcia Sanz R, Gonzalez D, Grand D, Håkansson A, Hummel M, Liu H, Lombardia L, Macintyre EA, Milner B, Montes-Moreno S, Schuuring E, Spaargaren M, Hodges E, van Dongen JJM. EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations. Leukemia. 2012;26:2159–72.
Pongers-Willemse MJ, Seriu T, Stolz F, d’Aniello E, Gameiro P, Pisa P, Gonzalez M, Bartram CR, Panzer-Grümayer ER, Biondi A, San Miguel JF, van Dongen JJ. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia. Leukemia. 1999;13:110–8.
van Dongen JJ, Seriu T, Panzer-Grümayer ER, Biondi A, Pongers-Willemse MJ, Corral L, Stolz F, Schrappe M, Masera G, Kamps WA, Gadner H, van Wering ER, Ludwig WD, Basso G, de Bruijn MA, Cazzaniga G, Hettinger K, van der Does-van den Berg A, Hop WC, Riehm H, Bartram CR. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 1998 Nov 28;352(9142):1731–8.
van Dongen JJM, Langerak AW, Brüggemann M, Evans PA, Hummel M, Lavender L, Delabesse E, Davi F, Schuuring E, Garcia Sanz R, van Krieken JHJM, Droese J, Gonzalez D, Bastard C, Spaargaren M, San Miguel JF, Parreira A, Smith JF, Morgan G, Kneba M, Macintyre EA. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene rearrangements in suspect lymphoproliferations. Report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17:2257–317.
van Krieken JHJM, Langerak AW, Macintyre EA, Kneba M, Smith JL, Garcia Sanz R, Morgan GJ, Parreira A, Molina T, Cabeçadas J, Gaulard P, Jasani B, Garcia JF, Ott M, Hannsmann ML, Berger F, Hummel M, Davi F, Brüggemann M, Lavender FL, Schuuring EMD, Evans PAS, White H, Salles G, Groenen PJTA, Gameiro P, Pott Ch, van Dongen JJM. Improved reliability of lymphoma diagnostics via PCR-based clonality testing. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia. 2007;21:201–6.
van der Velden VH, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, van Dongen JJ. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia. 2003;17:1013–34.
van der Velden VH, Panzer-Grümayer ER, Cazzaniga G, Flohr T, Sutton R, Schrauder A, Basso G, Schrappe M, Wijkhuijs JM, Konrad M, Bartram CR, Masera G, Biondi A, van Dongen JJ. Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting. Leukemia. 2007;21:706–13.
van der Velden VH, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER, Flohr T, Sutton R, Cave H, Madsen HO, Cayuela JM, Trka J, Eckert C, Foroni L, Zur Stadt U, Beldjord K, Raff T, van der Schoot CE, van Dongen JJ. European Study Group on MRD detection in ALL (ESG-MRD-ALL). Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia. 2007b;21:604–11.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Langerak, A.W., van der Velden, V.H.J. (2017). Molecular Diagnostics of Lymphoid Malignancies. In: van Pelt-Verkuil, E., van Leeuwen, W., te Witt, R. (eds) Molecular Diagnostics. Springer, Singapore. https://doi.org/10.1007/978-981-10-4511-0_6
Download citation
DOI: https://doi.org/10.1007/978-981-10-4511-0_6
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-10-4510-3
Online ISBN: 978-981-10-4511-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)